Publicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (17)

2020

  1. Development of a multicriteria decision analysis framework for evaluating and positioning oncologic treatments in clinical practice

    Journal of Oncology Practice

2019

  1. Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG performance status of 2

    Journal of Clinical Oncology

2018

  1. A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients

    Targeted Oncology, Vol. 13, Núm. 1, pp. 69-78

  2. Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients (Targeted Oncology, (2018), 13, 1, (69-78), 10.1007/s11523-017-0536-z)

    Targeted Oncology

  3. First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

    Breast Cancer Research and Treatment, Vol. 169, Núm. 3, pp. 469-479

  4. Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3126-3133

2017

  1. Assessment of HER2 status in resected gastric cancer in European population

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, pp. iii15

2016

  1. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

  2. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial

    Annals of Oncology, Vol. 27, pp. vi68

  3. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

    Oncotarget, Vol. 7, Núm. 25, pp. 37680-37692

  4. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: Results of the PANCOSTABRAX study

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 4, pp. 579-589

  2. Erratum: Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study [Support Care Cancer, DOI 10.1007/s00520-015-2809-3]

    Supportive Care in Cancer

  3. Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

    Supportive Care in Cancer, Vol. 23, Núm. 9, pp. 2833-2840

  4. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

    Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 731-737

2012

  1. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: A report of three cases

    Medical Oncology, Vol. 29, Núm. 2, pp. 795-798

2010

  1. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1536-1541